ClinicalTrials.gg

Esophagitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 123 studies for Esophagitis across more than 10 countries. 15 are recruiting or about to start. 54 of them are mainly about Esophagitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-24. Counting its 2 narrower conditions too, such as Eosinophilic Esophagitis: 413 studies, 82 open.

Status

Completed
78
Status unknown
14
Terminated
11
Recruiting
10
Active, not recruiting
3
Not yet recruiting
3

Phase

Phase 2
32
Phase 3
32
Phase 4
8
Phase 1
8
Early Phase 1
2

Where

United States
65
Korea, Republic of
12
China
11
Canada
10
United Kingdom
10
Japan
8

Who develops what

Add Esophagitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months. Compare Daewoong Pharmaceutical and Humanis Saglık Anonim Sirketi here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DWC202517Recent, limited
Evidence
  • NCT07746518 · Daewoong Pharmaceutical Co. LTD. · Phase 3 · live · comparator · “DWC202517 15 mg” · registered Jul 2026
—11 study
EsomeprazoleRecent, limited
Evidence
  • NCT05443984 · Jeil Pharmaceutical Co., Ltd. · Phase 3 · comparator · “Esomeprazole 40mg” · registered Jun 2022
  • NCT03943992 · Yooyoung Pharmaceutical Co., Ltd. · Phase 3 · comparator · “Nexium 40mg” · registered Mar 2019
  • NCT03736369 · Daewoong Pharmaceutical Co. LTD. · Phase 3 · comparator · “Esomeprazole 40mg” · registered Oct 2018
  • NCT03615677 · Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Phase 3 · comparator · “Esomeprazole 40mg” · registered Jul 2018
  • NCT03006874 · HK inno.N Corporation · Phase 3 · comparator · “Esomeprazole 40mg” · registered Jun 2016
AstraZeneca71% of its industry studiesUS: off-patent, 34 generics marketedEU: HALEON (EMA 2013)11 study
RabeprazoleRecent, limited
Evidence
  • NCT05604261 · Sihuan Pharmaceutical Holdings Group Ltd. · Phase 2 · comparator · “Rabeprazole sodium 20 mg” · registered Oct 2022
Eisai Co., Ltd.32% of its industry studiesUS: off-patent, 6 generics marketed11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Esophagitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Proton pump inhibitors (PPIs) 10 · Corticosteroids 3

Coming up

3studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger. 2 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.

Recruiting studies that take each age, of 10
AgeWomenMen
102 (20%)2 (20%)
187 (70%)7 (70%)
309 (90%)9 (90%)
409 (90%)9 (90%)
509 (90%)9 (90%)
658 (80%)8 (80%)
756 (60%)6 (60%)
856 (60%)6 (60%)

Across all 123 studies, recruiting or not: 43% stop at 75 or younger and 21% at 65; 23% take children; 1% are for women only and 2% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Esophagitis studies take

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 324 mo11–34 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 123. Browse all 123 → or search them.